13F-HR: Johnson & Johnson Q1 2026 Holdings Report

Johnson & Johnson's Q1 2026 13F filing reveals a diverse portfolio of investments, with a significant focus on biotechnology and healthcare innovation.

Summary

• Johnson & Johnson, through its investment manager, filed its Form 13F for the quarter ended March 31, 2026.
• The filing reports holdings in 16 different securities.
• The total value of these holdings amounts to $652,355,946.
• The primary investment manager is Johnson & Johnson, with one other included manager: Johnson & Johnson Innovation - JJDC, Inc.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a standard disclosure of holdings without performance data or strategic commentary.

Positives

• Significant investment in a diversified portfolio of 16 securities, indicating a broad approach to healthcare and biotechnology.
• Total portfolio value of over $652 million demonstrates substantial capital allocation.
• The inclusion of Johnson & Johnson Innovation - JJDC, Inc. as an included manager highlights a strategic focus on innovation within the healthcare sector.

Negatives

• The filing does not provide performance data for the reported holdings, making it impossible to assess the profitability or losses of these investments.
• Specific details regarding the investment strategy or rationale behind each holding are not disclosed.

Risks

• Investments in biotechnology and early-stage companies carry inherent risks due to the speculative nature of drug development and market adoption.
• Market volatility in the healthcare and biotech sectors could negatively impact the value of the reported holdings.
• Regulatory changes within the pharmaceutical and healthcare industries could affect the performance of portfolio companies.

Future Outlook

The filing itself is a historical report of holdings and does not contain forward-looking statements or guidance regarding future performance of the investments.

Management Comments

• The filing represents that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form.

Industry Context

StockSavvy.ai notes that Johnson & Johnson's continued investment in a diverse range of biotechnology and healthcare companies, as evidenced by this 13F filing, aligns with the broader industry trend of large pharmaceutical companies seeking to bolster their pipelines through strategic acquisitions and investments in innovative startups.

Comparison to Industry Standards

• Johnson & Johnson's reported portfolio value of $652 million is substantial, placing it among significant institutional investors in the healthcare and biotech sectors.
• The specific holdings, such as significant positions in Contineum Therapeutics Inc., CVRx, Inc., and Protagonist Therapeutics Inc., reflect a strategic focus on areas like gene therapy, medical devices, and novel drug development, which are key growth areas for the industry.
• Compared to other large pharmaceutical companies that also engage in venture capital-style investments, Johnson & Johnson's approach appears to be diversified across multiple therapeutic areas and stages of development.

Stakeholder Impact

• Shareholders: The investments may lead to future returns if the portfolio companies are successful, potentially increasing shareholder value.
• Employees: Continued investment in innovation can secure the company's future and potentially lead to job growth.
• Suppliers and Creditors: The financial health and investment strategy of Johnson & Johnson impact its ability to meet its obligations.

Next Steps

• Monitor future 13F filings from Johnson & Johnson to observe changes in their investment portfolio.
• Track the performance of the individual companies listed in the holdings report to assess the success of Johnson & Johnson's investment strategy.

Key Dates

Keywords

Johnson & Johnson, Form 13F, Investment Holdings, Biotechnology, Healthcare, SEC Filing, Portfolio Management, Institutional Investor